A Prospective, Open-label, Dose Escalation (Part A) and Cohort Expansion (Part B) Phase 1 Study to Investigate the Safety, Tolerability, and Immunogenicity and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancers
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2016
At a glance
- Drugs GC 1118A (Primary)
- Indications Colorectal cancer; Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Green Cross
- 04 Jul 2016 Two part study changed to three part study; Part C (biweekly administration of GC 1118) added hence treatment revised.
- 04 Jul 2016 Planned number of patients changed from 66 to 72.
- 07 Jun 2016 Interim results (n=24) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology